Growth

GHRP-6

Hexapeptide · GHS-R agonist · 6 amino acids

FDA · CATEGORY 2 (2023)WADA PROHIBITED

Half-life

~25 minutes

Very short

minsdays

Route

SubQ injection

Evidence

Preclinical only

Risk

Moderate

Overview

Known for

Growth hormone releasing peptide. Similar to GHRP-2 but causes even MORE intense hunger. Strong GH release. The hunger effect is the main distinguishing feature — problematic for fat loss but useful for appetite stimulation.

Mechanism

First-generation GH secretagogue. Strong GH release BUT extreme hunger stimulation + cortisol/prolactin increase. Least selective GHRP.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Secondary
Supply & nature
SecretagogueSecretagogue
FDA category
Category 2 (2023)

Evidence & standing

Evidence base
Preclinical only
Risk level
Moderate
Best studies
4 references
  • Bowers et al. (1984) J Clin Endocrinol Metab 59:1040-47 — Original discovery
  • Arvat et al. (1997) JCEM 82:2252-56 — Appetite & GH release
  • NOT FDA APPROVED
  • WADA prohibited substance

Dosage & protocol

Typical dose
100-300mcg
Research range
100–300 µg
Cycle
4 weeks on / 4 weeks off
Onset
0 days first effects
Full effect
70 days
Half-life
~20-30min
~20-30 minutes (very short)
Protocol

100-300mcg per injection, 2-3x daily fasted.

Time to effects

EARLY: Immediate hunger

FULL: 8-12 weeks

Immediate: Ravenous hunger 15-20 minutes post-injection. This is unmistakable.

Week 2-4: GH-mediated recovery and sleep improvements.

Week 8-12: Body composition changes if diet is managed despite hunger.

The hunger is the 'effect' you feel first. GH benefits follow the same 8-12 week timeline as other GHRPs.

Recommended vial
  • 5mg vials

At 300mcg/day, 5mg = ~17 days ✓. 10mg = 33 days ✓. Same as GHRP-2.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Fully Reversible
WADA status
WADA – Prohibited (class to verify)
Side effects

Extreme hunger (40%+ — can be uncontrollable), water retention, cortisol spike, prolactin elevation, flushing, dizziness

Interactions

Somatostatin analogs. Insulin (hunger + hypoglycaemia risk).

Do not combine
CJC-1295 NO DAC 5mg + Ipamorelin 5mg (Blend)CJC-1295 NO DAC 5mg + Ipamorelin 5mg (Blend) GHRP-2GHRP-2 HexarelinHexarelin HGH 191 AA (97%)HGH 191 AA (97%) IpamorelinIpamorelin

Handle with research caution

  • Do NOT combine with exogenous HGH
  • Do NOT combine with GHRP-2 or Hexarelin (pick one GHRP)
  • ⚠️ Do NOT combine with GLP-1 agonists if fat loss is the goal (GHRP-6 hunger directly counteracts appetite suppression)

Storage & handling

Lyophilised
12–24 months
2–8°C
Reconstituted
4–6 weeks
2–8°C

Videos & talks

Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.

Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.